litlas
ログインアカウント作成

Stephen C. Bain

1994–2025 年に発表

102
論文数
22,668
被引用数
57
h 指数
95
i10 指数

被引用数

Stephen C. Bain の年別被引用数1983 年: 被引用 1 件1994 年: 被引用 5 件1995 年: 被引用 48 件1996 年: 被引用 59 件1997 年: 被引用 77 件1998 年: 被引用 63 件1999 年: 被引用 65 件2000 年: 被引用 57 件2001 年: 被引用 75 件2002 年: 被引用 62 件2003 年: 被引用 44 件2004 年: 被引用 40 件2005 年: 被引用 64 件2006 年: 被引用 53 件2007 年: 被引用 33 件2008 年: 被引用 37 件2009 年: 被引用 35 件2010 年: 被引用 38 件2011 年: 被引用 28 件2012 年: 被引用 33 件2013 年: 被引用 40 件2014 年: 被引用 52 件2015 年: 被引用 60 件2016 年: 被引用 49 件2017 年: 被引用 136 件2018 年: 被引用 213 件2019 年: 被引用 681 件2020 年: 被引用 821 件2021 年: 被引用 865 件2022 年: 被引用 783 件2023 年: 被引用 763 件2024 年: 被引用 1,504 件2025 年: 被引用 1,103 件2026 年: 被引用 56 件1984〜1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,242 件、この内訳の 21.1%イギリス: 引用元論文 1,046 件、この内訳の 9.9%中国: 引用元論文 580 件、この内訳の 5.5%イタリア: 引用元論文 565 件、この内訳の 5.3%カナダ: 引用元論文 525 件、この内訳の 5%デンマーク: 引用元論文 524 件、この内訳の 4.9%ドイツ: 引用元論文 483 件、この内訳の 4.6%オーストラリア: 引用元論文 368 件、この内訳の 3.5%スペイン: 引用元論文 281 件、この内訳の 2.6%フランス: 引用元論文 260 件、この内訳の 2.5%日本: 引用元論文 258 件、この内訳の 2.4%スウェーデン: 引用元論文 234 件、この内訳の 2.2%
0%21.1%その他 30.5%

機関

分野

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13%
  • Immunology and Microbiology1.2%
  • Neuroscience1.2%
  • Health Professions0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • その他2.1%

トピック

  • Diabetes Treatment and Management18.6%
  • Diabetes Management and Research6.9%
  • Pancreatic function and diabetes6.4%
  • Metabolism, Diabetes, and Cancer4.9%
  • Pharmacology and Obesity Treatment3.4%
  • Bariatric Surgery and Outcomes3.3%
  • その他56.5%

共著者

全論文

検索で開く
  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    著者: Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll - New England Journal of Medicine 2016 被引用: 6,603

  2. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    著者: Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain - New England Journal of Medicine 2019 被引用: 1,932

  3. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

    著者: Christopher Sorli, Shin‐ichi Harashima, George Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas K. Hansen, Stephen C. Bain - The Lancet Diabetes & Endocrinology 2017 被引用: 707

  4. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

    著者: Carel W. le Roux, Arne Astrup, Ken Fujioka, Frank L. Greenway, David Lau, Luc Van Gaal, Rafael Violante Ortíz, John Wilding, Trine Vang Skjøth, Linda Shapiro Manning, F. Xavier Pi‐Sunyer, A. Hamann, Alain Barakat, Matthias Blüher, Thomas Linn, Andrea Mölle, Alexander Segner, Petra Stübler, Regina Tosch-Sisting, Furio Pacini, Ferruccio Santini, Giulio Marchesini, Carlo Maria Rotella, Cecilia Invitti, Roberto Vettor, Silvio Buscemi, Pedro Mezquita Raya, Felipe Casanueva Freijoo, Ramón Gomis de Barbará, Raffaele Carraro, Enrique Romero Bobillo, Carmen de la Cuesta, Csaba Farsang, Albert Császár, Barbara Zahorska‐Markiewicz, Danuta Pupek-Musialik, Edward Franek, Lucyna Ostrowska, Magdalena Olszanecka‐Glinianowicz, Nebojša Lalić, Dragan Micić, Bernhard Ludvik, Bernhard Paulweber, Rudolf Prager, André Scheen, Luc Van Gaal, Arne Astrup, Kjeld Hermansen, Sten Madsbad, Aila Rissanen, Sakari Nieminen, Markku J. Savolainen, Michel Krempf, Monique Romon, M. Laville, Michel Marre, R Mira, Francis Finucane, Aletha Veenendaal, Frank van Berkum, Solrun Johannsson-Vidarsdóttir, V. Van de Walle, Eelco W. Meesters, Jøran Hjelmesæth, Tor Ole Klemsdal, Bård Kulseng, Birgit Bach-Kliegel, Kurt Laederach, Lukas Villiger, Alain Golay, Stefan Bilz, Thozhukat Sathyapalan, Stephen C. Bain, Sudhesh Kumar, Carel Wynard le Roux, Michael E. J. Lean, Barbara McGowan, Michael E.J. Lean, John Wilding, Gary Wittert, Ian Caterson, Joeseph Proietto, John Prins, Bruno Geloneze Neto, Jorge Luiz Gross, Antônio Roberto Chacra, Alfredo Halpern, Henrique Suplicy, Francis Chun Chung Chow, Hemant Thacker, Manoj Chadha, Hemaraj Chandalia, AG Unnikrishnan, Sanjay Kalra, Neeta Deshpande, Minakshi Shunmugavelu, Vaishali Deshmukh, Maximo Maislos, G. Lieberman, Ilan Shimon ほか 104 名 - The Lancet 2017 被引用: 844

  5. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives

    著者: Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi - Diabetes Metabolic Syndrome and Obesity 2021 被引用: 427

  6. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

    著者: Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, John B. Buse, Thomas Idorn, Kenneth W. Mahaffey, Johannes F.E. Mann, Michael A. Nauck, Søren Rasmussen, Peter Rossing, Benjamin Ole Wolthers, Bernard Zinman, Vlado Perkovic - Circulation 2021 被引用: 238

  7. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

    著者: Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh, John Deanfield, Silvio E. Inzucchi, Rodica Pop‐Busui, Johannes F.E. Mann, Scott S. Emerson, Neil R Poulter, Mads D.M. Engelmann, Maria Sejersten Ripa, G. Kees Hovingh, Kirstine Brown‐Frandsen, Stephen C. Bain, Matthew A. Cavender, Mette Gislum, Jens‐Peter David, John B. Buse - New England Journal of Medicine 2025 被引用: 301

  8. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

    著者: Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe, J. Hans DeVries - The Lancet Diabetes & Endocrinology 2017 被引用: 443

  9. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives

    著者: Marc Evans, Ruth D. Lewis, Angharad R. Morgan, Martin Whyte, Wasim Hanif, Stephen C. Bain, Sarah Davies, Umesh Dashora, Zaheer Yousef, Dipesh Patel, W. David Strain - Advances in Therapy 2021 被引用: 305

  10. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

    著者: Tina Vilsbøll, Stephen C. Bain, Lawrence A. Leiter, Ildiko Lingvay, David Matthews, Rafael Simó, Ida Carøe Helmark, Nelun Wijayasinghe, Michael Larsen - Diabetes Obesity and Metabolism 2017 被引用: 294

  11. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

    著者: Thinzar Min, Stephen C. Bain - Diabetes Therapy 2020 被引用: 273

  12. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

    著者: Stephen C. Bain, Michael A. Klufas, Allen C. Ho, David Matthews - Diabetes Obesity and Metabolism 2018 被引用: 293

  13. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

    著者: Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, Samy Hadjadj, Jack Lawson, Ofri Mosenzon, Søren Rasmussen, Stephen C. Bain - Kidney International 2023 被引用: 126

  14. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

    著者: Julio Rosenstock, Stephen C. Bain, Amoolya Gowda, Esteban Jódar, Bo Liang, Ildiko Lingvay, Tomoyuki Nishida, Roberto Trevisan, Ofri Mosenzon - New England Journal of Medicine 2023 被引用: 149

  15. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

    著者: Matthias von Herrath, Stephen C. Bain, Bruce W. Bode, Jesper O. Clausen, Ken Coppieters, Leylya Gaysina, Janusz Gumprecht, Troels Krarup Hansen, Chantal Mathieu, Cristóbal Morales, Ofri Mosenzon, Stine Segel, George Tsoukas, Thomas R. Pieber, Bernhard Ludvik, Rudolf Prager, Bernhard Paulweber, Christoph Ebenbichler, Bart Keymeulen, Christophe De Block, Loren D. Grossman, Robyn L. Houlden, Patrice Perron, Thomas Ransom, Peter Senior, S. John Weisnagel, Vincent Woo, R Dumas, David Thompson, Tina Vilsbøll, Jeppe Gram, Claus Bogh Juhl, Janne Hukkanen, Jorma Lahtela, Leo Niskanen, Donal O’Shea, Timothy O’Brien, Séamus Sreenan, Julio Wainstein, Moshe Phillip, Hilla Knobler, Francesco Dotta, Pier Marco Piatti, Roberto Trevisan, Agostino Gnasso, Hanne L. Gulseth, John Cooper, Ewa Pańkowska, Monika Łukaszewicz, Bogumił Wolnik, Isabel Manita, Olinda Marques, Cristina Roque, Rosa Maria Príncipe, Celestino Neves, Susana Heitor, L. A. Ruyatkina, I. V. Dvoryashina, Gulnar Vagapova, Lidiya Belousova, M. Sergeeva-Kondrachenko, А. Б. Песков, Elena Frolova, Albina Golovach, М. А. Куницына, N Krasnopeeva, Irina Ipatko, Carmen De la Cuesta, Francisco J. Tinahones, Mercedes Rigla, Juan Francisco Merino-Torres, Luis Alberto Gómez, Mercè Fernández, Rafael Simó, Mikael Rydén, Johan Jendle, Karin Filipsson, Björn Eliasson, Borys Mankovsky, Iurii Lymar, Liubov Sokolova, Galyna Myshanych, Tetiana Zlova, М.V. Vlasenkо, Petro Kuskalo -, Hamish Courtney, Colin Dayan, Patrick English, Simon Heller, A.B. Johnson, Sunil Nair, Richard David Leslie, Parth Narendran, Nick Oliver, Shenaz Ramtoola, J. H. F. Shaw, Adie Viljoen, Amer Al‐Karadsheh, Jean M. Dostou, Sumana Gangi ほか 13 名 - The Lancet Diabetes & Endocrinology 2021 被引用: 178

  16. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

    著者: Mansoor Husain, Stephen C. Bain, Ole Kleist Jeppesen, Ildiko Lingvay, Rasmus Sørrig, Marianne Bach Treppendahl, Tina Vilsbøll - Diabetes Obesity and Metabolism 2020 被引用: 209

  17. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

    著者: John B. Buse, Stephen C. Bain, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Richard E. Pratley, Martin Linder, Tea Monk Fries, David D. Ørsted, Bernard Zinman - Diabetes Care 2020 被引用: 169

  18. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

    著者: Steven P. Marso, Florian M.M. Baeres, Stephen C. Bain, Bryan Goldman, Mansoor Husain, Michael A. Nauck, Neil R Poulter, Richard E. Pratley, Anne Bloch Thomsen, John B. Buse - Journal of the American College of Cardiology 2020 被引用: 111

  19. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

    著者: Ketan Dhatariya, Stephen C. Bain, John B. Buse, Richard J. Simpson, Lise Tarnow, Margit S. Kaltoft, Michael Stellfeld, Karen Tornøe, Richard E. Pratley - Diabetes Care 2018 被引用: 131

  20. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

    著者: Melanie J. Davies, Stephen C. Bain, Stephen L. Atkin, Peter Rossing, David A. Scott, Минара Шамхаловна Шамхалова, Heidrun Bosch‐Traberg, Annika Syrén, Guillermo E. Umpierrez - Diabetes Care 2015 被引用: 228

  21. Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

    著者: Subodh Verma, Darren K. McGuire, Stephen C. Bain, Deepak L. Bhatt, Lawrence A. Leiter, C. David Mazer, Tea Monk Fries, Richard E. Pratley, Søren Rasmussen, Hrvoje Vražić, Bernard Zinman, John B. Buse - Diabetes Obesity and Metabolism 2020 被引用: 93

  22. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

    著者: Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C. Bain, Serge Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde, DEPICT-2 Investigators, Cecilia Luquez, Federico Pérez Manghi, María Rosa Ulla, Maria Alejandra Moisello, Virginia Visco, Silvia Gorban De Lapertoza, Silvana Ernestina Solís, Javier Farias, Georgina Sposetti, Pieter Gillard, Pascale Abrams, M. van Ypersele de Strihou, James R. W. Conway, Sue D. Pedersen, Peter Senior, Joanne Liutkus, Churn-Ern Yip, Zubin Punthakee, Frédéric Bernier, Heather Lochnan, Vincent Woo, Thomas G. Elliott, Juan Palma, C Merino, Alfredo Danin Vargas, Ulrich Wendisch, Andreas Reichel, Jochen Seufert, Bernd Becker, Hasan Alawi, Andreas L. Birkenfeld, Christoph Hasslacher, Joerg Luedemann, Thomas Schaum, Cornelia Marck, Joachim Sauter, Ulrich Aigner, Yukiko Onishi, Hiroaki Seino, Yuichi Sato, Kiyohide Nunoi, Akira Yamauchi, Eitaro Nakashima, Hiroki Ikeda, Toshihiko Shiraiwa, Yoshimitsu Yamasaki, Hiroki Yokoyama, Kunihiko Nakamura, Masayuki Noritake, Shozo Miyauchi, Tomomi Hakoda, Yoshihide Hirohata, Atsushi Hasegawa, Yoshihide Fukumoto, Hirotaka Nagashima, Masahiro Takihata, Tetsuro Kamada, Hideaki Jinnouchi, Yuri Ono, Takayuki Watanabe, Hiroshi Ohashi, Masahiko Takai, T Seguchi, Katsuya Yamazaki, Hajime Maeda, Shingo Iwasaki, Harold W. de Valk, Adriaan Kooy, S.A.N.T. Landewé-Cleuren, Katarzyna Madziarska, Andrzej Stankiewicz, Katarzyna Wasilewska, Gottfried Rudofsky, Maciej T. Małecki, Ewa Pańkowska, Ewa Szyprowska, Monika Łukaszewicz, Lidia Tokarska, Ирина Аркадьевна Бондарь, I. V. Karpova, Ludmila Ruyatkina, Alsu Gafurovna Zalevskaya, Ruslan Sardinov, Yury Khalimov, Folke Sjöberg, Pekka Koskinen ほか 63 名 - Diabetes Care 2018 被引用: 252

  23. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    著者: Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas K. Hansen, Ingrid Holst, Ildiko Lingvay - Cardiovascular Diabetology 2019 被引用: 162

  24. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke

    著者: Subodh Verma, Neil R Poulter, Deepak L. Bhatt, Stephen C. Bain, John B. Buse, Lawrence A. Leiter, Michael A. Nauck, Richard E. Pratley, Bernard Zinman, David D. Ørsted, Tea Monk Fries, Søren Rasmussen, Steven P. Marso - Circulation 2018 被引用: 119